PDF herunterladen
Kinder- und Jugendmedizin 2017; 17(04): 217-224
DOI: 10.1055/s-0038-1629421
Infektionskrankheiten und Impfprävention
Schattauer GmbH

Impfprävention

Empfehlungen und aktuelle DatenPrevention through vaccinationRecommendations and an update
M. Knuf
1   Klinik für Kinder und Jugendliche, HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden
2   Zentrum für Kinder- und Jugendmedizin, Universitätsmedizin Mainz
,
F. Zepp
2   Zentrum für Kinder- und Jugendmedizin, Universitätsmedizin Mainz
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Eingereicht am: 30. Juni 2017

angenommen am: 03. Juli 2017

Publikationsdatum:
24. Januar 2018 (online)

    Lizenzen und Reprints

Zusammenfassung

Erstmalig hat die STIKO evidenzbasierte Hinweise zur Schmerz- und Stressreduktion beim Impfen publiziert. Schmerz und Stress beeinflussen die Akzeptanz von Impfungen. Es liegen Empfehlungen zu Injektionstechniken, altersabhängigen Ablenkungsmethoden und weiteren Verhaltensweisen vor. Langzeitdaten zur Persistenz von anti-HBsKonzentrationen 30 Jahre nach der Grundimmunisierung mit einem Hepatitis-B-Impfstoff belegen die Induktion einer Gedächtnisantwort bzw. die Stabilität der Antikörperspiegel. Anti-HBs-Titer fallen in Abhängigkeit vom Impfalter unterschiedlich aus. Pertussis-Epidemien treten in Ländern mit niedriger Durchimpfungsquote alle 3–4 Jahre zyklisch auf. Neuere Daten aus Deutschland belegen, dass das Erkrankungsalter bei Pertussis zunimmt und die Impfimmunität kürzer andauert als ursprünglich angenommen. Azelluläre Pertussis-Impfstoffe sind allgemein schlechter wirksam als Ganzkeim-Impfstoffe. Säuglinge erkranken am häufigsten. Das Auftreten von Pertactin-defizienten Pertussis-Stämmen scheint für den Wirkungsverlust der Impfstoffe von Bedeutung zu sein. Es werden Daten zur Sicherheit der Rotavirus-, HPV- und MMR-Impfung sowie zum Auftreten von Impfgranulomen besprochen.

Summary

For the first time, STIKO published evidence-based information on pain and stress reduction during vaccination. Pain and stress affect the acceptance of vaccinations. There are recommendations on injection techniques, age-dependent deflection methods and other behaviors.

Long-term data on the persistence of anti-HBs concentrations 30 years after the basic immunization with a hepatitis B vaccine demonstrate the induction of a memory response and the stability of the antibody levels. Anti-HBs titres vary depending on the age of vaccination. Pertussis epidemics occur cyclically every 3 to 4 years in countries with low vaccination rates. Recent data from Germany show that the disease age increases with pertussis and the vaccine immunity is shorter than originally assumed. Accellular pertussis vaccines are generally less effective than whole-seed vaccines. Infants develop most frequently. The occurrence of pertactin-deficient pertussis strains appears to be important for the loss of potency of the vaccines. Data on the safety of rotavirus, HPV and MMR vaccination as well as on the appearance of vaccine granulomas are discussed.

Schlüsselwörter

Schmerz- und Stressreduktion beim Impfen - Langzeitimmunität nach Hepatitis-B-Impfung - Pertussis in Deutschland - Wirksamkeit von Pertussis-Impfstoffen - Impfstoffsicherheit

Keywords

Pain and stress reduction during vaccination - long-term immunity after hepatitis B vaccination - pertussis in Germany - efficacy of pertussis vaccines - vaccine safety
 

  • Literatur

  • 1 http://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Impfempfehlungen_node.html
  • 2 RKI. Epidemiologisches Bulletin, Nr. 34 2016
    PubMedGoogle Scholar
  • 3 Report to SAGE: on reducing pain and distress at the time of vaccination. Geneva: SAGE Technical Consultation Group on Reducing Pain and Distress at the Time of Vaccination; 2015. Einsehbar www.who.int/immunization/sage/meetings/2015/april/1_SAGE_latest_pain_guidelines_March_24_Final.pdf (zugegriffen: 23.6.2016)
  • 4 Berrang J, Vosschulte P, Zernikow B. Schmerzreduktion bei Blutabnahmen und Injektionen. In Zernikow (Hrsg). B. Schmerztherapie bei Kindern, Jugendlichen und jungen Erwachsenen.. Berlin, Heidelberg: Springer; 2015: 355-367.
    Google Scholar
  • 5 Boerner KE, Birnie KA, Chambers CT. et al Simple psychological interventions for reducing pain from common needle procedures in adults: systematic review of randomized and quasi-randomized controlled trials. Clin J Pain 2015; 31: 90
    CrossrefPubMedGoogle Scholar
  • 6 SAGE. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2015; conclusions and recommendations. WER 2015; 22: 261-280.
    Google Scholar
  • 7 Taddio A, McMurtry CM, Shah V. et al Reducing pain during vaccine injections: clinical practice guideline. CMAJ 2015; 187: 975-982.
    CrossrefPubMedGoogle Scholar
  • 8 WHO. Reducing pain at the time of vaccination WHO position paper -September 2015. Weekly Epidemiological Record 2015; 90: 505-516.
    PubMedGoogle Scholar
  • 9 Bundeszentrale für gesundheitliche Aufklärung www.Impfen-Info.de
  • 10 Bruce MG, Bruden D, Hurlburt D. et al Antibody levels and protection after Hepatitis B vaccine: results of a 30-year follow-up study and response to a Booster Dose. J Infect Dis 2016; 214: 16-22.
    CrossrefPubMedGoogle Scholar
  • 11 Coppola N, Corvino AR, De Pascalis S. et al The long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy. BMC Infect Dis 2015; 15: 149
    CrossrefPubMedGoogle Scholar
  • 12 Dissertation Silvia Klein. Zusammenhang zwischen Impfungen und Inzidenz und Mortalität von Infektionskrankheiten. Zeitreihenanalysen mit Meldedaten zu Diphtherie, Pertussis, Poliomyelitis und Tetanus von 1892 bis 2011 in Deutschland RKI 2013 S. 144 ff. http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000095132
    PubMedGoogle Scholar
  • 13 Epidemiologischen Bulletin Nr. 1 2014
    PubMed
  • 14 Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2015, Datenstand: 1. März 2016 S 127 ff
    PubMed
  • 15 Schwartz KL, Kwong JC, Deeks SL. et al Effectiveness of pertussis vaccination and duration of immunity. CMAJ 2016; 188: E399-E406.
    CrossrefPubMedGoogle Scholar
  • 16 Klein NP, Bartlett J, Rowhani-Rahbar A. et al Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012; 367: 1012-1019.
    CrossrefPubMedGoogle Scholar
  • 17 Baxter R, Bartlett J, Rowhani-Rahbar A. et al Effectiveness of pertussis vaccines for adolescents and adults: case-control study. BMJ 2013; 347: f4249
    CrossrefPubMedGoogle Scholar
  • 18 Tartof SY, Lewis M, Kenyon C. et al Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013; 131: e1047-1052.
    CrossrefPubMedGoogle Scholar
  • 19 McGirr A, Fisman DN. Duration of pertussis immunity after DTaP immunization: a meta-analysis. Pediatrics 2015; 135: 331-343.
    CrossrefPubMedGoogle Scholar
  • 20 Tomovici A, Barreto L, Zickler P. et al Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine 2012; 30: 2647-2653.
    CrossrefPubMedGoogle Scholar
  • 21 Martin SW, Pawloski L, Williams M. et al Pertactin-negative Bordetella pertussis strains: Evidence for a possible selective advantage. Clin Infect Dis 2015; 60: 223-227.
    CrossrefPubMedGoogle Scholar
  • 22 Hiramatsu Y, Miyaji Y, Otsuka N. et al Significant decrease in pertactin-deficient Bordetella pertussis isolates, Japan. Emerg Infect Dis 2017; 23: 699-701.
    CrossrefPubMedGoogle Scholar
  • 23 Zeddeman A, van MGent, Heuvelman CJ. et al. Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012 Euro Surveill. 2014; 19 pii 20881
    PubMedGoogle Scholar
  • 24 Burdin N, Handy LK, Plotkin SA. What is wrong with pertussis vaccine immunity? The problem of waning effectiveness of pertussis Vaccines. Cold Spring Harb Perspect Biol 2017; Mar 13 pii a029454. [Epub ahead of print]
    PubMedGoogle Scholar
  • 25 Koch J, Harder T, von Kries R. et al The risk of intussusception after rotavirus vaccination - a systematic literature review and meta-analysis. Dtsch Arztebl Int 2017; 114: 255-262.
    PubMedGoogle Scholar
  • 26 Andrews N, Stowe J, Miller E. No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England. Vaccine 2017; 35: 1729-1732.
    CrossrefPubMedGoogle Scholar
  • 27 Gerber JS, Offit PA. Vaccines and Autism: A Tale of shifting hypotheses. CID 2009; 48: 456-461.
    CrossrefPubMedGoogle Scholar
  • 28 Knuf M, Kieninger-Baum D, Habermehl P. et al Sicherheit und Verträglichkeit von Impfstoffen. Pädiatrische Praxis 2017; 87: 409-429.
    Google Scholar
  • 29 Fombonne E, Chakrabarti S. No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics 2001; 108: E58
    CrossrefPubMedGoogle Scholar
  • 30 Madsen KM, Hviid A, Vestergaard M. et al A population-based study of measles, mumps, and rubella vaccination and autism. The N Engl J Med 2002; 347: 1477-1482.
    CrossrefPubMedGoogle Scholar
  • 31 Uchiyama T, Kurosawa M, Inaba Y. MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. J Autism Dev Disord 2007; 37: 210-217.
    CrossrefPubMedGoogle Scholar
  • 32 Jain A, Marshall J, Buikema A. et al Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA 2015; 313: 1534-1540.
    CrossrefPubMedGoogle Scholar
  • 33 DeStefano F, Bhasin TK, Thompson WW. et al Age at first measles-mumps-rubella vaccination in children with autism and schoolmatched control subjects: a population-based study in metropolitan Atlanta. Pediatrics 2004; 113: 259-266.
    CrossrefPubMedGoogle Scholar
  • 34 Mrozek-Budzyn D, Kiełtyka A, Majewska R. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatr Infect Dis J 2010; 29: 397-400.
    CrossrefPubMedGoogle Scholar
  • 35 Smeeth L, Cook C, Fombonne E. et al MMR vaccination and pervasive developmental disorders: a case-control study. Lancet 2004; 364: 963-969.
    CrossrefPubMedGoogle Scholar
  • 36 Uno Y, Uchiyama T, Kurosawa M. et al The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: the first case-control study in Asia. Vaccine 2012; 30: 4292-4298.
    CrossrefPubMedGoogle Scholar
  • 37 Uno Y, Uchiyama T, Kurosawa M. et al Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder. Vaccine 2015; 33: 2511-2516.
    CrossrefPubMedGoogle Scholar
  • 38 Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. J Child Psychol Psychiatry 2005; 46: 572-579.
    CrossrefPubMedGoogle Scholar
  • 39 Fombonne E, Zakarian R, Bennett A. et al Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 2006; 118: e139-50.
    CrossrefPubMedGoogle Scholar
  • 40 Taylor B, Miller E, Farrington CP. et al Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999; 353: 2026-2029.
    CrossrefPubMedGoogle Scholar
  • 41 Bergfors E, Hermansson G, Nyström Kronander U. et al How common are long-lasting, intensely itching vaccination granulomas and contact allergy to aluminium induced by currently used pediatric vaccines? A prospective cohort study. Eur J Pediatr 2014; 173: 1297-1307.
    CrossrefPubMedGoogle Scholar
  • 42 Mäkelä A, Nuorti JP, Peltola H. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 2002; 110: 957-963.
    CrossrefPubMedGoogle Scholar
  • 43 Demicheli V, Rivetti A, Debalini MG. et al. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev 2005; Oct 19 (04) CD004407
    PubMedGoogle Scholar
  • 44 Taylor LE, Swerdfeger AL, Eslick GD. et al Vaccines are not associated with autism: an evidence- based meta-analysis of case-control and cohort studies. Vaccine 2014; 32: 3623-3629.
    CrossrefPubMedGoogle Scholar